Clinical Trials

Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

224 enrolled

Ovarian Neoplasms

NCT03842982 2026-03-16

CHIPPI

362 enrolled

Ovarian Neoplasms

NCT07214779 2026-03-16

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled

Ovarian Neoplasms

NCT06824467 2026-03-13

TroFuse-022

770 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07318558 2026-03-13

TroFuse-021

900 enrolled

Ovarian Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04575935 2026-03-05

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

580 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06819007 2026-03-05

DO-01

582 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07225270 2026-03-03

RAINFOL-04

528 enrolled

Ovarian Neoplasms

NCT04884360 2026-03-02

MONO-OLA1

366 enrolled

Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05445778 2026-02-23

GLORIOSA

520 enrolled

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05316181 2026-02-12

KOV-HIPEC-02R

140 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04169997 2026-01-28

FLAMES

404 enrolled

Ovarian Neoplasms

NCT03937154 2026-01-27

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

BreastGynecologicThoracic

145 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT07286162 2026-01-27

CALM-TF

Phase 3 Not yet recruiting

300 enrolled

Ovarian Neoplasms, Recurrence

NCT04421963 2026-01-21

ROSY-O

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04095364 2026-01-14

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

880 enrolled

Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT05659381 2025-12-24

HOTT

220 enrolled